



PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Hasvold, et al.

Serial No.: 10/785,120

Filed: February 25, 2004

Title: HETEROCYCLIC KINASE
INHIBITORS

Case No.: 7034US01

Group Art No.: (not yet assigned)

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on:

Date of Deposit: May 13, 2004

Tanya Parent 5/13/04
Tanya Parent Date

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Dear Sir:

Enclosed herewith for the patent application identified above entitled HETEROCYCLIC KINASE INHIBITORS are the following:

1. Information Disclosure Statement;
2. Form PTO 1449, in duplicate;
3. References as cited on PTO 1449 (20 references); and
4. Return Receipt Postcard.

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.

Respectfully submitted,
Hasvold, et al.

ABBOTT LABORATORIES
Customer Number 23492
Telephone: (847) 935-7956
Facsimile: (847) 938-2623

Johanna M. Corbin
Johanna M. Corbin
Registration No. 51,582
Attorney for Applicants



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Hasvold, et al.

Serial No.: 10/785,120

Filed: February 25, 2004

Title: HETEROCYCLIC KINASE
INHIBITORS

Case No.: 7034US01

Group Art No.: (not yet assigned)

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on:

Date of Deposit: May 13, 2004

Tanya Parent 5/13/04
Tanya Parent Date

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed, to the knowledge of the undersigned, before the mailing date of a first Office Action on the merits. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.

Respectfully submitted,
Hasvold, et al.

ABBOTT LABORATORIES
Customer Number 23492
Telephone: (847) 935-7956
Facsimile: (847) 938-2623

Johanna M. Corbin
Johanna M. Corbin
Registration No. 51,582
Attorney for Applicants



DATE: May 13, 2004

SHEET 1_ of 2_

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98 (b))	ATTY. DOCKET NO. 7034US01	SERIAL NO. 10/785,120
	APPLICANT(S) Yunsong Tong et al.	
	FILING DATE February 25, 2004	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
	A1	2001/0027195		Nugiel et al.			
	A2	6,291,504	9/18/2001	Nugiel et al.			
	A3	6,297,238	10/02/2001	Doyle et al.			
	A4	6,407,103	06/18/2002	Nugiel et al.			
	A5	6,462,036	10/08/2002	Doyle et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRAN- SLATION YES NO
	B1	00/27822	18.05.2000	WO			
	B2	01/87846	22.11.2001	WO			
	B3	02/44174	06.06.2002	WO			
	B4	02/46182	13.06.2002	WO			
	B5	03/004491	16.01.2003	WO			
	B6	03/007883	30.01.2003	WO			
	B7	03/033499	24.04.2003	WO			
	B8	03/070236	28.08.2003	WO			
	B9	99/54308	28.10.1999	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	de Costa et al., "Synthesis, characterization, and biological evaluation of a novel class of <i>N</i> -(arylethyl)- <i>N</i> -alkyl-2-(1-pyrrolidinyl)ethylamines: Structural requirements and binding affinity at the σ receptor," J. Med. Chem. 35:38-47 (1992)
C2	Harris et al., "Improved functional group compatibility in the palladium-catalyzed synthesis of aryl amines," Organic Letters 4(17):2885-2888 (2002)
C3	Lemek et al., "Synthesis of selectively deuterated nitrobenzene derivatives," Tetrahedron 57:4753-4757 (2001)
C4	Nugiel et al., "Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitors," J. Med. Chem. 44:1334-1336 (2001)

	C5	Nugiel et al., "Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 2. Probing the indeno ring substituent pattern," J. Med. Chem. 45:5224-5232 (2002)
	C6	Yue et al., "Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3 ^{1,2} ," J. Med. Chem. 45:5233-5248

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)

DATE: May 13, 2004

SHEET 1_ of 2_

Form PTO - 1449 (Modified)

FORM PTO-1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		7034US01	10/785,120
		APPLICANT(S) Yunsong Tong et al.	
(37 CFR 1.98 (b))		FILING DATE February 25, 2004	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
	A1	2001/0027195		Nugiel et al.			
	A2	6,291,504	9/18/2001	Nugiel et al.			
	A3	6,297,238	10/02/2001	Doyle et al.			
	A4	6,407,103	06/18/2002	Nugiel et al.			
	A5	6,462,036	10/08/2002	Doyle et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO
	B1	00/27822	18.05.2000	WO			
	B2	01/87846	22.11.2001	WO			
	B3	02/44174	06.06.2002	WO			
	B4	02/46182	13.06.2002	WO			
	B5	03/004491	16.01.2003	WO			
	B6	03/007883	30.01.2003	WO			
	B7	03/033499	24.04.2003	WO			
	B8	03/070236	28.08.2003	WO			
	B9	99/54308	28.10.1999	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	C1	de Costa et al., "Synthesis, characterization, and biological evaluation of a novel class of <i>N</i> -(arylethyl)- <i>N</i> -alkyl-2-(1-pyrrolidinyl)ethylamines: Structural requirements and binding affinity at the σ receptor," J. Med. Chem. 35:38-47 (1992)
	C2	Harris et al., "Improved functional group compatibility in the palladium-catalyzed synthesis of aryl amines," Organic Letters 4(17):2885-2888 (2002)
	C3	Lemek et al., "Synthesis of selectively deuterated nitrobenzene derivatives," Tetrahedron 57:4753-4757 (2001)
	C4	Nugiel et al., "Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitors," J. Med. Chem. 44:1334-1336 (2001)

	C5	Nugiel et al., "Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 2. Probing the indeno ring substituent pattern," J. Med. Chem. 45:5224-5232 (2002)
	C6	Yue et al., "Synthesis and evaluation of indenopyrazoles as cyclin-dependent kinase inhibitors. 3. Structure activity relationships at C3 ^{1,2} ," J. Med. Chem. 45:5233-5248

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)